06:27:33 EDT Sun 21 Jul 2024
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save

Q:PBYI - PUMA BIOTECHNOLOGY INC - http://www.pumabiotechnology.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
PBYI - Q1.03.61·4.361.03.66-0.04-1.1250.27592,6033.70  3.70  3.547.73  2.1316:02:34Jul 1815 min RT 2¢

Recent Trades - Last 10 of 2603
Time ETExPriceChangeVolume
16:02:34Q3.66-0.04828
16:01:47Q3.66-0.04436
16:01:16Q3.67-0.0310
16:01:16Q3.730.03490
16:00:04Q3.66-0.043
16:00:04Q3.66-0.0497
16:00:04Q3.66-0.042
16:00:00Q3.66-0.04200
16:00:00Q3.66-0.04696
16:00:00Q3.66-0.042,396

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-07-18 16:10U:PBYINews ReleasePuma Biotechnology to Host Conference Call to Discuss Second Quarter 2024 Financial Results
2024-07-02 17:30U:PBYINews ReleasePuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2024-06-07 17:37U:PBYINews ReleasePuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2024-06-03 14:33U:PBYINews ReleasePuma Biotechnology Announces Presentation of Findings from a Phase I/Ib Study of Alisertib in Advanced EGFR-Mutated Lung Cancer
2024-06-02 10:01U:PBYINews ReleasePuma Biotechnology Announces Presentation of Findings from a Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (TBCRC 041)
2024-05-28 09:00U:PBYINews ReleasePuma Biotechnology to Join Russell 3000 Index
2024-05-23 17:15U:PBYINews ReleasePuma Biotechnology Announces Publication of Alisertib Abstract Titles for the 2024 ASCO Annual Meeting
2024-05-02 16:05U:PBYINews ReleasePuma Biotechnology Reports First Quarter Financial Results
2024-04-18 16:15U:PBYINews ReleasePuma Biotechnology to Host Conference Call to Discuss First Quarter 2024 Financial Results
2024-04-03 17:30U:PBYINews ReleasePuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2024-03-20 08:30U:PBYINews ReleasePuma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer
2024-02-29 16:05U:PBYINews ReleasePuma Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results
2024-02-27 18:30U:PBYINews ReleasePuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2024-02-22 16:10U:PBYINews ReleasePuma Biotechnology to Participate in a Panel Discussion at TD Cowen's 44th Annual Health Care Conference
2024-02-15 16:10U:PBYINews ReleasePuma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results
2024-02-13 08:30U:PBYINews ReleasePuma Biotechnology Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung Cancer
2024-01-11 16:07U:PBYINews ReleasePuma Biotechnology to Present at B. Riley Securities 4th Annual Oncology Conference
2023-12-11 08:30U:PBYINews ReleasePuma Biotechnology Announces Phase II Clinical Trial Design for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer
2023-11-06 17:15U:PBYINews ReleasePuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2023-11-02 16:05U:PBYINews ReleasePuma Biotechnology Reports Third Quarter 2023 Financial Results